COMMUNIQUÉS West-GlobeNewswire

Clementia présente ses résultats d’exploitation pour le deuxième trimestre de 2018 et fait le point sur son portefeuille de produits
09/08/2018
Le recrutement des patients pour l’essai de phase 3 MOVE sur le palovarotène pour le traitement de la fibrodysplasie ossifiante progressive (FOP) est sur la bonne voie; deux analyses intérimaires des données sont [...]
Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax
09/08/2018
Adds two revenue-generating FDA-licensed vaccines that protect against cholera and typhoid fever, both with dual-market potential Broadens development pipeline with an adenovirus 4/7 vaccine funded by the DoD for [...]
Cerecor Reports Second Quarter 2018 Financial Results
09/08/2018
BALTIMORE, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), an integrated biopharmaceutical company focused on pediatric healthcare and developing innovative therapies that make a difference in the lives [...]
RadNet Reports Second Quarter Financial Results to Include Record Revenue and Reaffirms Guidance Ranges
09/08/2018
Total Net Revenue increased 6.3% to $244.4 million in the second quarter of 2018 from $230.0 million in the second quarter of 2017 Adjusted EBITDA (1) increased 3.0% to $38.2 million in the second quarter of 2018 from $ [...]
Momenta Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
09/08/2018
CAMBRIDGE, Mass., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the second quarter ended June 30, 2018 and provided a corporate update. “The [...]
BeiGene Reports Second Quarter 2018 Financial Results
09/08/2018
CAMBRIDGE, Mass. and BEIJING, China, Aug. 09, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Release date of six-month interim report (Q2) 2018 and audio cast
09/08/2018
On Wednesday, 15 August 2018, ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) releases its interim report for the six months ended 30 June 2018. ALK will host a meeting for analysts and institutional investors that day at [...]
Nordic Transport Group Holding A/S announces preliminary result of takeover offer
09/08/2018
Company Announcement 9 August 2018 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH [...]
Gefion Group Investments A/S announces final result and withdrawal of takeover offer
09/08/2018
Company Announcement 9 August 2018 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH [...]
Active Biotech AB - Interim Report January - June 2018
09/08/2018
Second quarter in brief The company's partner NeoTX presented new preclinical data for ANYARA at the AACR Annual Meeting in Chicago The rights issue in April brought the company SEK 47.1 M Events after the end of the [...]
Notice of Nexstim Plc's Half-Yearly Report H1 2018
09/08/2018
Company announcement, Helsinki, 9 August 2018 at 9:00 AM Notice of Nexstim Plc's Half-Yearly Report H1 2018 Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or the " Company "), the targeted neuromodulation company [...]
Shire plc : Rule 2.9 Announcement
09/08/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 9 August 2018 [...]
Motif Bio to Present at Investor Events in August and September
09/08/2018
NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will [...]
Basilea starts clinical phase 3 study with antibiotic ceftobiprole in Staphylococcus aureus bacteremia (SAB)
09/08/2018
Basel, Switzerland, August 09, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the start of a clinical phase 3 study with its antibiotic ceftobiprole. The registration study evaluates the safety and [...]
Spring Bank Announces Pricing of Public Offering of Common Stock
09/08/2018
HOPKINTON, Mass. and NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at [...]
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/08/2018
MENLO PARK, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies [...]
Precision Therapeutics to Hold Business Update Conference Call on August 14, 2018
08/08/2018
MINNEAPOLIS, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery [...]
Sienna Senior Living Inc. Reports 2018 Second Quarter Financial Results and Announces 2% Dividend Increase
08/08/2018
MARKHAM, Ontario, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced its financial results for the three and six months ended June 30, 2018. The [...]
Helix BioPharma Corp. Closes Private Placement
08/08/2018
RICHMOND HILL, Ontario, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and [...]

Pages